Objectives There is an association between serum thyrotropin (TSH) and lipid profile. However, there is a little information regarding the relation between subclinical hypothyroidism (SCH), atherogenic indices and inflammation in polycystic ovary syndrome (PCOS). Herein, we aimed to evaluate the impact of SCH on lipids and inflammatory markers in newly diagnosed PCOS patients. Methods Two groups were performed for total 99 PCOS patients: SCH (TSH>2.5 mIU/L) and euthyroid groups (TSH<2.5 mIU/L). Complete blood count, lipids, atherogenic indices were evaluated, inflammatory markers as platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR), monocyte/high density lipoprotein ratio (MHR) and mean platelet volume/platelet ratio (MPR) were calculated. Results SCH group had higher WBC, PLT, PCT, PLR, MPR and non-high density lipoprotein cholesterol levels. Differences between MHR, total cholesterol/HDL cholesterol (TC/HDL), triglycerides/HDL cholesterol (TG/HDL) and low density lipoprotein/HDL cholesterol (LDL/HDL) levels were significantly higher (p=0.001; 0.01; 0.01; 0.02, respectively), TC/HDL cholesterol levels were positively correlated with TSH (p=0.028, r=0.402) in SCH group. TC/HDL levels were also correlated with WBC, PLT, PDW, PCT, MPR and MHR (p=0.003; 0.011; 0.031; 0.037; 0.006; 0.002; r=0.515; 0.442; −0.382; 0.370; −0.471; 0.523, repectively). Conclusions TC/HDL and MHR may serve as beneficial markers for evaluating the inflammatory state of PCOS with SCH. Screening thyroid hormones and curing SCH in PCOS may lower lipids, decelerate developing hypothyroidism and cardiovascular morbidities.
The most common microvascular complication of diabetes is diabetic retinopathy (DR). A new and recently emerged marker of oxidative stress and inflammation is monocyte to high-density lipoprotein cholesterol ratio (MHR). Platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) have also been shown as they are biomarkers of systemic inflammation in various diseases. The present study aims to assess MHR, its predictive value and relations between other inflammation markers in DR patients. Materials and Methods: Sixty-eight patients with DR, fifty-four DM patients without DR and forty-two control subjects were included in this study. Complete blood count, lipoprotein and uric acid levels were recorded. MHR was calculated. Results: MHR, NLR and PLR were statistically significantly higher in DR group than DM without DR group (p=0.008, p=0.042, p=0.003, respectively). Then, receiver operating characteristic (ROC) curve analysis was performed and pointed that MHR predicted DR using a cutoff level of 0.0156 with 63% sensitivity and 76% specificity. Conclusion: In this study, we investigated MHR in DR patients and its relationship with other inflammatory markers, lipoproteins and uric acid. We suggested that an elevated admission of MHR may be of benefit to detect DR and to determine the CVD risk of these patients.
IntroductionElevated cardiotrophin-1 (CT-1) and leptin levels are important risk factors for cardiovascular diseases (CVDs). Obstructive sleep apnea syndrome (OSAS) has also been reported to increase this risk. The aim of this study is to evaluate serum concentrations of CT-1 and leptin in patients with OSAS and whether there is a possible association between CT-1, leptin and OSAS severity.Material and methodsFifty newly diagnosed OSAS patients and thirty nonapneic snoring subjects participated in this study. Fasting serum lipid profile markers were evaluated. The measurements of serum CT-1 and leptin levels were carried out using human ELISA kits.ResultsSignificant differences were found in the serum CT-1 and leptin levels between the two groups. Serum median CT-1 levels in patient and control groups, respectively, were 19.47; 8.23 pg/ml and leptin levels were 2.07; 1.29 ng/ml (p < 0.001). In the severe patient group, serum median CT-1 level was statistically significantly higher than the median level in the mild/moderate group. There was no correlation between patients’ leptin and lipid profile parameters and CT-1 concentrations were not associated with triglyceride, cholesterol or LDL cholesterol levels except HDL cholesterol: CT-1 levels were positively correlated with HDL levels (p = 0.02).ConclusionsBoth CT-1 and leptin were significantly elevated in the patient group. Furthermore, CT-1 and leptin were associated with OSAS and CT-1 was associated with the disease severity.
Objective: The percentage of large unstained cells (%LUCs) reflects peroxidase-negative cells and activated lymphocytes. Unlike other infections, the value of %LUCs in the diagnosis of fungal infections is not clear. We aimed to evaluate %LUCs and its correlations with other inflammatory parameters of invasive aspergillosis (IA) patients. Methods: Twenty patients and 20 healthy participants were included. Full blood count parameters including %LUCs values were recorded. Platelet to lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), eosinophil to lymphocyte ratio (ELR) were calculated. Results: There was a significant difference between the study groups for %LUCs [2.40 (2.22–3.25); 1.43 (1.25–2.10), respectively; p<0.001]. Furthermore, %LUCs were statistically significantly correlated with PLR, NLR and MLR (p=0.020, 0.040, 0.040; respectively) but not correlated with ELR (p>0.05). Conclusion: The %LUCs values were significantly increased and correlated with markers of inflammation in patients. We suggest that the %LUCs is a useful predictor and may be an aid in the diagnosis and/or the management of IA and may help clinicians for follow up these patients in therapy process. Our study provides target pathways for further studies in the diagnosis of Aspergillus-infected patients using inflammatory parameters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.